Who We Are



Asalyxa Bio is focused on the rapid development of a revolutionary innate immune cell targeting platform to create first-in-class particle drug products for diseases with continuing high unmet medical needs.   With an expert team of drug developers and business leaders, Asalyxa is committed to developing revolutionary therapeutics to help patients enjoy a healthier tomorrow 

The PANTHER Platform


PANTHER: (Poly-Aspirin Nanoparticle THERapeutics) reimagines the treatment of human disease.  With safety in mind at the onset, the biodegradable poly-aspirin backbone of PANTHER breaks down into salicylic acid (a well-known and safe anti-inflammatory agent) and adipic acid (a food additive classified as GRAS by the FDA).  The well-established scientific understanding of these components, based on decades of patient experience, makes them ideal building blocks for the PANTHER platform. 


The versatility of Asalyxa’s PANTHER platform allows for the creation of particles of different shapes and sizes and character to target specific immune cell types.  Furthermore, these particles can be loaded with other well-established or novel drugs providing targeted, or depot delivery, increasing efficacy and/or safety of these molecules.   


By targeting specific immune cells, the PANTHER platform allows for the tailored modulation of inflammatory responses, while at the same time, not turning the immune system off.  This innovative therapeutic approach can deliver therapeutics for diseases where treatments are limited or do not exist, such as in ARDS, COVID-19, other acute tissue injuries, and a wide-range of conditions driven by dysregulated response of the innate immune system.



ASX-100 is the first particle-based therapeutic from the PANTHER platform.  A microsphere about the same size as a bacteria, ASX-100 is recognized by neutrophils and monocytes, both types of innate immune cells, in the body as a foreign invader.  These cells, then, ingest the ASX-100 microparticles where they began to degrade, releasing salicylic acid and calming an over-reactionary inflammatory response.  This prevents systemic immune cell recruitment cellular migration through the vasculature to the local site of disease, without affecting the local and necessary immune response. and reduces key inflammatory markers.  ASX-100 is first being developed for the treatment of ARDS and COVID-19.  

Acute Respiratory Distress Syndrome (ARDS)


ARDS is one area of high unmet medical need, with approximately 500,000 Americans and 1.5 million patients in major global markets suffering from this deadly condition each year. Of the patients that get ARDS, approximately 50% of them die regardless of the original cause of respiratory distress. Additionally, ARDS is the leading killer of COVID-19 patients, due to an over-reactive immune response to respiratory stress, often described as a “cytokine storm”. There are NO approved therapeutics for ARDS.  The standard of care is “best supportive care” provided by ventilation.

Further, this same over-reactive immune response is also associated with many of the other serious life-threatening acute conditions including acute lung injury, acute kidney injury, and acute hepatic injury. Additionally, neutrophils contribute to many other inflammatory and immune-related diseases. Recent literature suggests they may also play a role in certain manifestations of cancer. These are all areas of potential future development of the platform.






Asalyxa is committed to addressing the COVID-19 crisis. In the COVID-19 setting, Asalyxa's particle based therapy is expected to decrease the time patients are on ventilators – or possibly eliminate the need for mechanical ventilation – and reduce the tendency for systemic clotting (cause of strokes, acute lung failure, heart tissue damage, and loss of circulation to limbs).    

Asalyxa has been in contact with government regulators to ensure the appropriate development plans are in place to ensure the fastest, safest path to patients is achieved. Asalyxa has also committed to provide drugs for the treatment of COVID-19 in a manner that is affordable and accessible to all.